Fucai Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fucai Wang has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Zhihan Zhou
School of Medicine, Huaqiao University, Quanzhou 362021, China
2 shared publications - Chen Zhu
School of Medicine, Huaqiao University, Quanzhou 362021, China
1 shared publication - Chenrui Ji
School of Medicine, Huaqiao University, Quanzhou 362021, China
1 shared publication - Genrui Zhang
School of Medicine, Huaqiao University, Quanzhou 362021, China
1 shared publication - Hao Wu
School of Medicine, Huaqiao University, Quanzhou 362021, China
1 shared publication - Junbo Huang
School of Medicine, Huaqiao University, Quanzhou 362021, China
1 shared publication
Latest Publications
- Open Access
- 27 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (9) , 3869
Umbrella Systematic Review of the Efficacy and Safety of PD-1 Inhibitors Combined with CTLA-4 Inhibitors in the Treatment of Melanoma
The objective is to assess the effectiveness and safety of combining PD-1 inhibitors with CTLA-4 inhibitors for melanoma treatment, drawing on current meta-analysis findings and evaluating the supporting evidence. We used medical subject words and free text words (such as “PD-1 inhibitor”, “CTLA-4 inhibitor”, “melanoma”) as search keywords to search the literature in six literature databases from the establishment of the database to 11 April 2025. Using the PICO (Participant, Intervention, Control, and Outcome) framework, we identified 27 unique associations between combination treatment efficacy outcomes and 70 unique associations between adverse event outcomes, which were re-evaluated using a random effects model. A total of 10 meta-analysis were included, including 36 randomized controlled trials and two retrospective studies. According to the evaluation meta-analysis of AMSTAR 2 (A MeaSurement Tool to Assess Systematic Reviews, version 2), all 10 meta-analysis were of very low quality. The association of outcome indicators was re-analyzed based on the random effects model, of which 26 associations showed high efficacy of combination therapy and 66 associations showed poor safety of combination therapy. In conclusion, a PD-1 inhibitor combined with a CTLA-4 inhibitor is a very effective method for the treatment of melanoma, but the incidence of various types of adverse reactions is high, and the evidence is not reliable. Therefore, future studies need higher quality evidence.
- 27 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (9) , 3869
Open AccessUmbrella Systematic Review of the Efficacy and Safety of PD-1 Inhibitors Combined with CTLA-4 Inhibitors in the Treatment of Melanoma
The objective is to assess the effectiveness and safety of combining PD-1 inhibitors with CTLA-4 inhibitors for melanoma treatment, drawing on current meta-analysis findings and evaluating the supporting evidence. We used medical subject words and free text words (such as “PD-1 inhibitor”, “CTLA-4 inhibitor”, “melanoma”) as search keywords to search the literature in six literature databases from the establishment of the database to 11 April 2025. Using the PICO (Participant, Intervention, Control, and Outcome) framework, we identified 27 unique associations between combination treatment efficacy outcomes and 70 unique associations between adverse event outcomes, which were re-evaluated using a random effects model. A total of 10 meta-analysis were included, including 36 randomized controlled trials and two retrospective studies. According to the evaluation meta-analysis of AMSTAR 2 (A MeaSurement Tool to Assess Systematic Reviews, version 2), all 10 meta-analysis were of very low quality. The association of outcome indicators was re-analyzed based on the random effects model, of which 26 associations showed high efficacy of combination therapy and 66 associations showed poor safety of combination therapy. In conclusion, a PD-1 inhibitor combined with a CTLA-4 inhibitor is a very effective method for the treatment of melanoma, but the incidence of various types of adverse reactions is high, and the evidence is not reliable. Therefore, future studies need higher quality evidence.
- Open Access
- 27 October 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (11) , 887
HMGB1 and Its Signaling Pathway in Osteosarcoma: Current Advances in Targeted Therapy
This article reviews the research progress for high-mobility group protein B1 (HMGB1) and its signaling pathway in osteosarcoma (OS) and discusses its application potential in targeted therapy. A large number of domestic and foreign studies were reviewed to summarize the research results on the the biological function, signal pathway regulation mechanism, and intervention strategy of HMGB1 in recent years. HMGB1 promotes OS cell proliferation, invasion, and immune escape by activating RAGE, TLR4, and downstream MAPK, NF-κB, and PI3K/AKT signaling pathways. Interfering with HMGB1 or its signaling axis shows good antitumor potential in in vitro and in vivo models, but clinical transformation is still limited by its dual biological effects and tumor heterogeneity. HMGB1 and its related signaling pathways are important targets for the treatment of osteosarcoma. In the future, the development of a multi-channel combined intervention and efficient delivery system will provide a new direction for improving the therapeutic effect.
- 27 October 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (11) , 887
Open AccessHMGB1 and Its Signaling Pathway in Osteosarcoma: Current Advances in Targeted Therapy
This article reviews the research progress for high-mobility group protein B1 (HMGB1) and its signaling pathway in osteosarcoma (OS) and discusses its application potential in targeted therapy. A large number of domestic and foreign studies were reviewed to summarize the research results on the the biological function, signal pathway regulation mechanism, and intervention strategy of HMGB1 in recent years. HMGB1 promotes OS cell proliferation, invasion, and immune escape by activating RAGE, TLR4, and downstream MAPK, NF-κB, and PI3K/AKT signaling pathways. Interfering with HMGB1 or its signaling axis shows good antitumor potential in in vitro and in vivo models, but clinical transformation is still limited by its dual biological effects and tumor heterogeneity. HMGB1 and its related signaling pathways are important targets for the treatment of osteosarcoma. In the future, the development of a multi-channel combined intervention and efficient delivery system will provide a new direction for improving the therapeutic effect.
- Open Access
- 17 October 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (10) , 2389
ROS-Mediated Necroptosis Promotes Coxsackievirus B3 Replication and Myocardial Injury
Coxsackievirus B3 (CVB3) is a primary causative agent of viral myocarditis (VMC), which can lead to both acute and chronic cardiac inflammation accompanied by progressive heart failure and arrhythmias. Although CVB3 has been implicated in various forms of programmed cell death, whether it triggers necroptosis and the underlying mechanisms remains unclear. This study aimed to investigate the role and mechanism of CVB3-induced necroptosis and its effect on viral replication. Using both in vitro and in vivo models, we demonstrated that CVB3 infection significantly upregulates the expression of key necroptotic markers RIP1 and RIP3 in HeLa cells and mouse myocardial tissues. This upregulation was accompanied by elevated intracellular reactive oxygen species (ROS) levels and suppression of the Nrf2/HO-1 antioxidant pathway. Intervention with the necroptosis inhibitor Necrostatin-1 (Nec-1) or the ROS scavenger N-acetylcysteine (NAC) markedly attenuated cell death, suppressed viral replication, and ameliorated myocardial injury and inflammatory responses in infected mice. Mechanistically, CVB3 inhibits the Nrf2/HO-1 pathway, thereby inducing substantial ROS accumulation that promotes necroptosis. This effect can be reversed by NAC treatment. Our study reveals a novel mechanism through which CVB3 induces ROS-dependent necroptosis via the suppression of the Nrf2/HO-1 pathway, providing new insights into the pathogenesis of viral myocarditis and suggesting potential therapeutic strategies.
- 17 October 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (10) , 2389
Open AccessROS-Mediated Necroptosis Promotes Coxsackievirus B3 Replication and Myocardial Injury
Coxsackievirus B3 (CVB3) is a primary causative agent of viral myocarditis (VMC), which can lead to both acute and chronic cardiac inflammation accompanied by progressive heart failure and arrhythmias. Although CVB3 has been implicated in various forms of programmed cell death, whether it triggers necroptosis and the underlying mechanisms remains unclear. This study aimed to investigate the role and mechanism of CVB3-induced necroptosis and its effect on viral replication. Using both in vitro and in vivo models, we demonstrated that CVB3 infection significantly upregulates the expression of key necroptotic markers RIP1 and RIP3 in HeLa cells and mouse myocardial tissues. This upregulation was accompanied by elevated intracellular reactive oxygen species (ROS) levels and suppression of the Nrf2/HO-1 antioxidant pathway. Intervention with the necroptosis inhibitor Necrostatin-1 (Nec-1) or the ROS scavenger N-acetylcysteine (NAC) markedly attenuated cell death, suppressed viral replication, and ameliorated myocardial injury and inflammatory responses in infected mice. Mechanistically, CVB3 inhibits the Nrf2/HO-1 pathway, thereby inducing substantial ROS accumulation that promotes necroptosis. This effect can be reversed by NAC treatment. Our study reveals a novel mechanism through which CVB3 induces ROS-dependent necroptosis via the suppression of the Nrf2/HO-1 pathway, providing new insights into the pathogenesis of viral myocarditis and suggesting potential therapeutic strategies.